{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+II&page=2", "query": { "intervention": "Part II", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+II&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-13T09:16:26.008Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04435691", "title": "Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Magrolimab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2020-07-28", "completion_date": "2025-03-25", "has_results": true, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-09-13T09:16:26.008Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04435691" }, { "nct_id": "NCT04167618", "title": "177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Medulloblastoma, Childhood" ], "interventions": [ { "name": "177Lu-DTPA-omburtamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Y-mAbs Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "19 Years", "sex": "ALL", "summary": "3 Years to 19 Years" }, "enrollment_count": 2, "start_date": "2021-09-30", "completion_date": "2022-08-11", "has_results": true, "last_update_posted_date": "2023-10-06", "last_synced_at": "2026-09-13T09:16:26.008Z", "location_count": 4, "location_summary": "Rochester, Minnesota • New York, New York • Portland, Oregon + 1 more", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04167618" }, { "nct_id": "NCT01484470", "title": "Umbilical Cord Transplantation for the Elderly Population", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "StemEx", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Loyola University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "73 Years", "sex": "ALL", "summary": "55 Years to 73 Years" }, "enrollment_count": 18, "start_date": "2010-01", "completion_date": "2018-11-21", "has_results": false, "last_update_posted_date": "2019-08-21", "last_synced_at": "2026-09-13T09:16:26.008Z", "location_count": 1, "location_summary": "Maywood, Illinois", "locations": [ { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01484470" }, { "nct_id": "NCT00000912", "title": "A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Abacavir sulfate", "type": "DRUG" }, { "name": "Amprenavir", "type": "DRUG" }, { "name": "Nelfinavir mesylate", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" }, { "name": "Levocarnitine", "type": "DRUG" }, { "name": "Adefovir dipivoxil", "type": "DRUG" }, { "name": "Saquinavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 475, "start_date": null, "completion_date": "2000-05", "has_results": false, "last_update_posted_date": "2021-10-29", "last_synced_at": "2026-09-13T09:16:26.008Z", "location_count": 44, "location_summary": "Los Angeles, California • Menlo Park, California • San Diego, California + 27 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Menlo Park", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000912" }, { "nct_id": "NCT04952753", "title": "Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "NIS793", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Modified FOLFOX6", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 204, "start_date": "2021-11-15", "completion_date": "2025-01-20", "has_results": false, "last_update_posted_date": "2025-03-26", "last_synced_at": "2026-09-13T09:16:26.008Z", "location_count": 7, "location_summary": "Los Angeles, California • Ann Arbor, Michigan • St Louis, Missouri + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04952753" }, { "nct_id": "NCT04684511", "title": "Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hemophilic Arthropathy" ], "interventions": [ { "name": "TRM-201 (Rofecoxib)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tremeau Pharmceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 2, "start_date": "2021-06-02", "completion_date": "2022-09-28", "has_results": false, "last_update_posted_date": "2022-10-27", "last_synced_at": "2026-09-13T09:16:26.008Z", "location_count": 19, "location_summary": "Los Angeles, California • Orange, California • Sacramento, California + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04684511" }, { "nct_id": "NCT04292119", "title": "Lorlatinib Combinations in Lung Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer", "Anaplastic Lymphoma Kinase Gene Translocation", "ROS1 Rearrangement", "Relapsed Cancer", "MET Amplification", "Resistant Cancer", "NSCLC" ], "interventions": [ { "name": "Lorlatinib", "type": "DRUG" }, { "name": "Crizotinib", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "TNO155", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2020-05-01", "completion_date": "2023-03-01", "has_results": false, "last_update_posted_date": "2021-03-10", "last_synced_at": "2026-09-13T09:16:26.008Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04292119" }, { "nct_id": "NCT03837899", "title": "Durvalumab and Tremelimumab for Pediatric Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pediatric Cancer", "Solid Tumor Pediatric", "Hematological Malignancies" ], "interventions": [ { "name": "Durvalumab / Tremelimumab Combination Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "0 Years to 18 Years" }, "enrollment_count": 50, "start_date": "2019-03-07", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-09-13T09:16:26.008Z", "location_count": 5, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • New Hyde Park, New York + 2 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Hyde Park", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03837899" }, { "nct_id": "NCT00911963", "title": "Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "VCH-222 or matching placebo", "type": "DRUG" }, { "name": "peginterferon alfa-2a", "type": "BIOLOGICAL" }, { "name": "ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 49, "start_date": "2009-04", "completion_date": "2012-09", "has_results": false, "last_update_posted_date": "2014-03-10", "last_synced_at": "2026-09-13T09:16:26.008Z", "location_count": 4, "location_summary": "Marietta, Georgia • Detroit, Michigan • Dallas, Texas + 1 more", "locations": [ { "city": "Marietta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00911963" }, { "nct_id": "NCT03699319", "title": "CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "CPI 613", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "5-flurouracil", "type": "DRUG" }, { "name": "Folinic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Bajor, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 49, "start_date": "2018-12-07", "completion_date": "2024-09-23", "has_results": false, "last_update_posted_date": "2025-01-23", "last_synced_at": "2026-09-13T09:16:26.008Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03699319" } ] }